Global Tramadol Drugs Market is Segmented By Dosage Form (Tablet, Capsule, Liquid, Others), By Route of Administration (Oral, Intravenous, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.
Tramadol Drugs Market Overview
Global Tramadol Drugs Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing with a CAGR of YY % during the forecast period 2023-2030.
Tramadol is a strong pain medication used to treat moderate to severe pain that is not being relieved by other types of pain medicines. Tramadol is a synthetic opioid and acts in the brain and spine (central nervous system) to reduce the amount of pain you feel. Tramadol is an opioid and, like other opioids, selectively binds to different opiate receptors in the central nervous system.
The liver enzyme, CYP2D6, converts tramadol to its active metabolite M1, which has a stronger affinity for the mu receptor compared to the inactive form. Tramadol does not bind to the mu receptor as much as morphine. Unlike other opioids, tramadol does not reverse its course completely after the administration of naloxone.
Tramadol Drugs Market Scope
| Metrics | Details |
| CAGR | YY% |
| Size Available for Years | 2021-2030 |
| Forecast Period | 2023-2030 |
| Data Availability | Value (US$) |
| Segments Covered | Dosage Form, Route of Administration, Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details of the report- Request for sample
Market Dynamics: Drivers and Restraints
Increasing prevalence of pain and pain disorders
The rise in the prevalence of pain and pain disorders is one of the significant key factors that will help the market to grow during the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC) updated factsheet, in the U.S. adults, about 58.5 million people had doctor-diagnosed arthritis and by 2040, an estimated 78.4 million adults will have doctor-diagnosed arthritis. Therefore, pain can have substantial impacts on bodily function and limitations on various activities, affecting various physiological and psychological processes. It causes hyperalgesia, sleep disturbance, immune system suppression, and muscle tension. The complications can vary depending on the age of the affected individual.
Furthermore, the tramadol drugs market is driven by various factors like a rise in the geriatric population, a rise in the number of surgical procedures and others that will help the market to grow during the forecast period.
Market Dynamics: Restraint
Complications associated with drugs are one of the restraining factors that hampers the market growth during the forecast period. The organs most commonly affected by tramadol are the central nervous system, neuromuscular, and gastrointestinal. The cardiovascular system, dermatologic system, endocrine, genitourinary, and visual system are also affected by tramadol. The most prevalent side effects are nausea, dizziness, constipation, vomiting, somnolence, and headache. They tend to occur during the initial treatment rather than maintenance doses of the drug. Serious side effects include respiratory depression, which may result in death.
Tramadol Drugs Market Segmentation
The global tramadol drugs market is segmented based on dosage form, route of administration, distribution channel and region.
The tablets segment from the dosage form segment accounted for approximately 41.7% of the tramadol drugs market share
The tablets segment from the dosage form segment accounted for approximately 41.7% and it is expected to be dominated during the forecast period. Tablets are a well-established and widely accepted oral dosage form. They are easy to swallow and convenient for patients to take, making them a preferred choice for many individuals, including those who need to manage chronic pain. Also, they offer precise dosage control, allowing for consistent and accurate administration of tramadol. This is crucial in pain management to ensure that patients receive the appropriate amount of medication for their pain relief.
For instance, in January 2023, Accord Healthcare launched Tramadol/Paracetamol 37.5 mg/325 mg tablets in packs of sixty film-coated tablets. These tablets are intended for symptomatic treatment of moderate to severe pain but should be used in combination with tramadol and paracetamol.
Moreover, in October 2021, The U.S. Food and Drug Administration (FDA) approved a combination pill containing celecoxib and tramadol (Seglentis) for the treatment of adults with acute pain severe enough to require an opioid analgesic and for which alternative treatments fail to provide adequate pain relief.
Global Tramadol Drugs Market Geographical Share
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the favourable initiatives, FDA approvals and aid from governments as well as significant research & development, expenditures in the region. Further, the region's prominence on patient-focused care, along with the availability of tramadol, specialized medical centres, and awareness, drives the demand for the market in the region.
For instance, in October 2021, The U.S. Food and Drug Administration (FDA) approved Seglentis (celecoxib and tramadol hydrochloride), a proprietary product developed by Esteve Pharmaceuticals' (ESTEVE) R&D team. It is an innovative first-in-class product comprised of a co-crystal form of celecoxib (an anti-inflammatory) and tramadol (an analgesic) for the treatment of acute pain in adults.1-9 This is ESTEVE's first proprietary research product to enter the United States market.
COVID-19 Impact Analysis
Covid 19 had a significant influence on the tramadol pharmaceuticals market, resulting in increased tension, anxiety, and mental health concerns for many people, exacerbating pain situations. Few COVID-19 patients had lasting symptoms, such as bodily aches and discomfort, that required tramadol to alleviate.
In addition, many elective operations and medical treatments were postponed in order to save healthcare resources and limit the danger of transmission. As a result, several patients were in excruciating agony and required tramadol for comfort. As a result, the aforementioned factors led to the market's development.
Competitive Landscape
The major global players in the market include Purdue Pharma, Mundipharma, Amneal Pharmaceuticals, Advacare Pharma, Vertical Pharmaceuticals, CSL Limited, Grunenthal Group, Hexal AG, Somacare, Akesiss Pharma and among others.
Key Developments
- In April 2023, Avenue Therapeutics, Inc., a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of rare and neurologic diseases, stated that it had received official meeting minutes from the Type C meeting with the U.S. Food and Drug Administration (“FDA”) conducted on March 9, 2023, regarding the development of intravenous (“IV”) Tramadol for the treatment of postoperative pain. The purpose of this meeting was to discuss and reach an agreement with the FDA on the proposed study protocol that would assess the risk of opioid-induced respiratory depression related to opioid stacking on IV Tramadol compared to IV morphine.
Why Purchase the Report?
- To visualize the global tramadol drugs market segmentation based on dosage form, route of administration, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of tramadol drugs market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global tramadol drugs market report would provide approximately 61 tables, 58 figures and 187 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
